Celyad Oncology SA (NASDAQ:CYAD – Get Rating) shares passed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $1.88 and traded as low as $1.79. Celyad Oncology shares last traded at $1.79, with a volume of 8,115 shares.

Celyad Oncology Stock Performance

The company has a debt-to-equity ratio of 0.05, a quick ratio of 2.58 and a current ratio of 1.71. The stock's 50 day simple moving average is $1.88 and its two-hundred day simple moving average is $2.08.

About Celyad Oncology

(Get Rating)

Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes.

Featured Articles

• Get a free copy of the StockNews.com research report on Celyad Oncology (CYAD)
• Could Snap Stock Rebound As Management Restructures?
• MarketBeat: Week in Review 8/29 – 9/2
• Hormel Looks Cheap At These Levels
• Lululemon Set To Soar Into September
• Could Nike Stock be Oversold, but Still Overvalued?

Receive News & Ratings for Celyad Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celyad Oncology and related companies with MarketBeat.com's FREE daily email newsletter.